Abstract
Primary thymic mucinous adenocarcinoma (PTMA) is an extremely rare neoplasm, although it is an aggressive disease with a poor prognosis. Chemotherapy and radiotherapy did not exhibit satisfactory anti-tumor efficacy, and complete resection of the tumor might be the most effective treatment.1-3 Therefore, there is no effective treatment for PTMA accompanied by distant metastasis, and it is necessary to evaluate the efficacy and safety of multimodal treatments including molecular targeted drugs and immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
